United States


ALVXM.PA on Paris Stock Exchange

25 Apr 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Wed, Apr 19 2017

BRIEF-Vexim: in Q1, 19 pct growth of sales at 4.7 million euros

* Continued growth and adoption of SpineJack in Q1 2017: +19 pct growth of sales at 4.7 million euros ($5.0 million)

BRIEF-Vexim launches Masterflow plus in Germany

* New product launch in Germany: Masterflow plus, a new product targeted at low energy osteoporotic fractures Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

BRIEF-Vexim FY operating loss narrows at 3.2 million euros

* FY operating loss 3.2 million euros ($3.46 million) versus loss of 4.8 million euros year ago

BRIEF-Vexim announces another major step towards SpineJack commercialization in US

* Finalizes recruitment of patients for international clinical study, supporting the 510 (k) regulatory approval application to the FDA

BRIEF-Vexim to initiate registration process of its products in China

* Strengthens its intellectual property protection for the Spinejack in Asia

Select another date:

More From Around the Web